Courtesy of
Courtesy of

Pfizer says three doses of its coronavirus vaccine will offer strong protection for children under the age of 5.

The drugmaker said Monday it will submit its findings to the federal officials later this week.

The United States’ 18 million children 5 and younger are the only age group not approved by federal authorities for a coronavirus vaccine.

The company discovered during its trials that two shots didn’t seem enough to combat the virus for preschoolers. As a result, a third shot was administered to more than 1,600 youngsters — from age 6 months to 4 years — during the winter surge of the omicron variant, The Associated Press reported.

The additional shot worked, Pfizer and its partner BioNTech said in a news release. AP reported preliminary data suggested the three-dose regimen is 80% effective in preventing symptomatic coronavirus, the companies said, but they cautioned the calculation is based on just 10 cases diagnosed among study participants by the end of April.

The study rules said at least 21 cases are required to assess the level of effectiveness. Dr. William Moss of the Johns Hopkins Bloomberg School of Public Health, who didn’t participate in the Pfizer study, said the results bode well for parents who want to have their young ones vaccinated in the near future, AP reported.

Leave a comment

Your email address will not be published.